Unformatted text preview: their own, while the jury is still out as to the effectiveness of Zetia as a stand-alone. Thus, when the patent on Zocor was about to expire, Vytorin was born in an effort to keep Zocor somewhat proprietary. But then came the ENHANCE study, which was to have verified the effectiveness of Vytorin (and to a lesser extent Zetia on its own) as a cholesterol-buster. The study was completed in April 2006, but not released until 21 months later—and only after Congress got in a huff and demanded that Merck and Schering-Plough get off their duffs and release the bloody thing. According to the study, about which the manufacturers would have most assuredly been well versed, Vytorin was shown to provide little, if any significant benefit in slowing the clogging of arteries when compared with generic, and far less-expensive statins....
View Full Document
- Summer '10
- Business Law, Atherosclerosis, Merck & Co., Statin, Schering-Plough Corporation, cholesterol drug, non-statin cholesterol drug